Cargando…
Cinobufagin exerts an antitumor effect in non-small-cell lung cancer by blocking STAT3 signaling
Background: Non-small-cell lung cancer (NSCLC) is the most common histological subtype of lung cancer with significant morbidity and mortality rates worldwide. Cinobufagin, the primary component of Chansu and the major active ingredient of cinobufacini, has attracted widespread attention for its exc...
Autores principales: | Yan, Sunshun, Ma, Chunbo, Zhou, Feng, Zheng, Hailun, Yang, Lehe, Xiao, Zhongxiang, Zhu, Jiandong, Zhao, Haiyang, Zhao, Chengguang, Xu, Xiaoling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622998/ https://www.ncbi.nlm.nih.gov/pubmed/37928418 http://dx.doi.org/10.7150/jca.86544 |
Ejemplares similares
-
Acetyl-cinobufagin suppresses triple-negative breast cancer progression by inhibiting the STAT3 pathway
por: Qi, Yufeng, et al.
Publicado: (2023) -
Celastrol elicits antitumor effects by inhibiting the STAT3 pathway through ROS accumulation in non-small cell lung cancer
por: Zhao, Zhucheng, et al.
Publicado: (2022) -
Flubendazole Elicits Antitumor Effects by Inhibiting STAT3 and Activating Autophagy in Non-small Cell Lung Cancer
por: Xie, Xiaona, et al.
Publicado: (2021) -
Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy
por: Lin, Shichong, et al.
Publicado: (2019) -
Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway
por: Yang, Lehe, et al.
Publicado: (2019)